"John's addition is another important strategic step in the continued growth of our intellectual property practice and considerably strengthens our pharmaceutical industry team," said Steve Hankins, head of Schiff Hardin's Intellectual Property group. "Having earned a Ph.D. in inorganic chemistry, John brings a great depth of knowledge in the field of science that will significantly expand our ability to serve our pharmaceutical clients. He will be a great resource to our many Washington D.C.-based clients and engagements."
Dr. Hsu's practice focuses on intellectual property litigation. He has deep experience in pharmaceutical litigation through his representation of generic drug manufacturers in high-stakes patent litigation brought under the Hatch-Waxman Act. He has represented clients in all phases of litigation (including both jury and bench trials) before the federal district courts, the Court of Appeals for the Federal Circuit, the Supreme Court of the United States, and the United States International Trade Commission. Dr. Hsu has also co-authored briefs submitted to the Supreme Court in a number of high-profile patent cases, including The Holmes Group, Inc. v. Vornado Air Circulations Systems, KSR Int'l Co. v. Teleflex, Inc., and EBay, Inc. v. MercExchange.
"Schiff Hardin is committed to providing clients a combination of excellent legal counsel with top tier technical experience, and John's background fits perfectly," said Marci A. Eisenstein, Managing Partner.
"John is an excellent patent litigator and an important addition to our pharma industry team," said Sailesh K. Patel, co-chair of Schiff Hardin's Pharmaceuticals and Biologics Patent Litigation team. "Biosimilar clearance work, additional Hatch-Waxman cases, and the ever-increasing number of inter partes reviews in the pharmaceutical space will all be key areas for the group and for John. I'm glad John decided to join our team during this fascinating time in patent law."
"I look forward to working alongside lawyers who dedicate time and resources toward building long-lasting relationships with their clients," said Dr. Hsu. "I am thrilled to be joining the Schiff team and look forward to further expanding the firm's practice in the pharmaceutical industry."
Dr. Hsu earned his J.D. from the University of Maryland School of Law and his Ph.D. in inorganic chemistry from the University of Maryland. He received a B.A. in biology from Johns Hopkins University.